Non-invasive intranasal delivery of quetiapine fumarate loaded microemulsion for brain targeting: Formulation, physicochemical and pharmacokinetic consideration

European Journal of Pharmaceutical Sciences

Volumn 91, Issue , 2016, Pages 196-207

  Shah, Brijesh ^a   Khunt, Dignesh ^b   Misra, Manju ^b   Padh, Harish ^c  

^a B V PATEL PHARMACEUTICAL EDUCATION AND RESEARCH DEVELOPMENT PERD CENTRE   (India)

^b NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER AHMEDABAD   (India)

^c SARDAR PATEL UNIVERSITY   (India)

Author keywords

Brain targeting; Chitosan; Intranasal route; Microemulsion; Quetiapine fumarate; Schizophrenia

Indexed keywords

CHITOSAN; LABRASOL; NOSE SPRAY; POLYSORBATE 80; QUETIAPINE; WATER; LIPID; NEUROLEPTIC AGENT; SURFACTANT;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CONTACT ANGLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG SOLUTION; GEOMETRY; LIPOPHILICITY; MAXIMUM PLASMA CONCENTRATION; MICROEMULSION; NONHUMAN; NOSE MUCOSA; PH; PHOTON CORRELATION SPECTROSCOPY; PHYSICAL CHEMISTRY; PLUME; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSMISSION ELECTRON MICROSCOPY; VISCOSITY; ZETA POTENTIAL; ANIMAL; BLOOD; CHEMISTRY; DRUG EFFECT; EMULSION; INTESTINE MUCOSA; INTRANASAL DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; METABOLISM; SPRAGUE DAWLEY RAT;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DRUG DELIVERY SYSTEMS; EMULSIONS; INTESTINAL MUCOSA; LIPIDS; NASAL MUCOSA; QUETIAPINE FUMARATE; RATS, SPRAGUE-DAWLEY; SURFACE-ACTIVE AGENTS;

EID: 84969584583     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2016.05.008     Document Type: Article

References (63)

1. Alam, M.I., Beg, S., Samad, A., Baboota, S., Kohli, K., Ali, J., Ahuja, A., Akbar, M., Strategy for effective brain drug delivery. Eur. J. Pharm. Sci. 40:5 (2010), 385–403.
2. Al-Mohizea, A.M., Influence of intestinal efflux pumps on the absorption and transport of furosemide. Saudi Pharm. J. 18:2 (2010), 97–101.
3. Al-Mohizea, A.M., Zawaneh, F., Alam, M.A., Al-Jenoobi, F.I., El-Maghraby, G.M., Effect of pharmaceutical excipients on the permeability of P-glycoprotein substrate. J. Drug Delivery Sci. Technol. 24:5 (2014), 491–495.
4. Amin, M.L., P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights 7 (2013), 27–34.
5. Artursson, P., Lindmark, T., Davis, S.S., Illum, L., Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm. Res. 11:9 (1994), 1358–1361.
6. Bshara, H., Osman, R., Mansour, S., El-Shamy, A.E.H.A., Chitosan and cyclodextrin in intranasal microemulsion for improved brain buspirone hydrochloride pharmacokinetics in rats. Carbohydr. Polym. 99 (2014), 297–305.
7. Cannon, J.B., LIPIDS—Strategies to formulate lipid-based drug delivery systems. Am. Pharm. Rev., 14(4), 2011, 84.
8. Carvalho, F.C., Bruschi, M.L., Evangelista, R.C., Gremião, M.P.D., Mucoadhesive drug delivery systems. Braz. J. Pharm. Sci. 46:1 (2010), 1–17.
9. Cheer, S.M., Wagstaff, A.J., Quetiapine. CNS drugs 18:3 (2004), 173–199.
10. Costa, P., Lobo, J.M.S., Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 13:2 (2001), 123–133.
11. Deli, M.A., Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochim. Biophys. Acta Biomembr. 1788:4 (2009), 892–910.
12. Dhuria, S.V., Hanson, L.R., Frey, W.H., Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J. Pharm. Sci. 99:4 (2010), 1654–1673.
13. FDA, US, Guidance for Industry: Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products — Chemistry, Manufacturing, and Controls Documentation. 2002, 1–49 Available From http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070575.pdf.
14. FDA, US, Draft Guidance for Industry: Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action. 2003, Center for Drug Evaluation and Research, US Department of Health and Human Services, Rockville (MD), 1–37 Available From http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070111.pdf.
15. Flens, M.J., Zaman, G.J., Van der Valk, P., Izquierdo, M.A., Schroeijers, A.B., Scheffer, G.L., Van der Groep, P., de Haas, M.M.C.J., Meijer, C.J., Scheper, R.J., Tissue distribution of the multidrug resistance protein. Am. J. Pathol., 148(4), 1996, 1237.
16. Florence, K., Manisha, L., Kumar, B.A., Ankur, K., Kumar, M.A., Ambikanandan, M., Intranasal clobazam delivery in the treatment of status epilepticus. J. Pharm. Sci. 100:2 (2011), 692–703.
17. Furubayashi, T., Inoue, D., Kamaguchi, A., Higashi, Y., Sakane, T., Influence of formulation viscosity on drug absorption following nasal application in rats. Drug Metab. Pharmacokinet. 22:3 (2007), 206–211.
18. Goldstein, J.M., Quetiapine fumarate (Seroquel): a new atypical antipsychotic. Drugs of today (Barcelona, Spain: 1998) 35:3 (1999), 193–210.
19. Graff, C.L., Pollack, G.M., P-glycoprotein attenuates brain uptake of substrates after nasal instillation. Pharm. Res. 20:8 (2003), 1225–1230.
20. Graff, C.L., Pollack, G.M., Functional evidence for P-glycoprotein at the nose-brain barrier. Pharm. Res. 22:1 (2005), 86–93.
21. Guo, C., Doub, W.H., The influence of actuation parameters on in vitro testing of nasal spray products. J. Pharm. Sci. 95:9 (2006), 2029–2040.
22. Haque, S., Md, S., Sahni, J.K., Ali, J., Baboota, S., Development and evaluation of brain targeted intranasal alginate nanoparticles for treatment of depression. J. Psychiatr. Res. 48:1 (2014), 1–12.
23. He, C.X., He, Z.G., Gao, J.Q., Microemulsions as drug delivery systems to improve the solubility and the bioavailability of poorly water-soluble drugs. Expert Opin. Drug Delivery 7:4 (2010), 445–460.
24. Hong, J.Y., Kim, J.K., Song, Y.K., Park, J.S., Kim, C.K., A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption. J. Control. Release 110:2 (2006), 332–338.
25. Illum, L., Chitosan and its use as a pharmaceutical excipient. Pharm. Res. 15 (1998), 1326–1331.
26. Illum, L., Transport of drugs from the nasal cavity to the central nervous system. Eur. J. Pharm. Sci. 11:1 (2000), 1–18.
27. Illum, L., Nasal drug delivery—possibilities, problems and solutions. J. Control. Release 87:1 (2003), 187–198.
28. Issa, M.M., Köping-Höggård, M., Artursson, P., Chitosan and the mucosal delivery of biotechnology drugs. Drug Discov. Today: Technologies 2:1 (2005), 1–6.
29. Kandimalla, K.K., Donovan, M.D., Localization and differential activity of P-glycoprotein in the bovine olfactory and nasal respiratory mucosae. Pharm. Res. 22:7 (2005), 1121–1128.
30. Kawakami, K., Yoshikawa, T., Moroto, Y., Kanaoka, E., Takahashi, K., Nishihara, Y., Masuda, K., Microemulsion formulation for enhanced absorption of poorly soluble drugs: I. Prescription design. J. Control. Release 81:1 (2002), 65–74.
31. Khan, M.S., Patil, K., Yeole, P., Gaikwad, R., Brain targeting studies on buspirone hydrochloride after intranasal administration of mucoadhesive formulation in rats. J. Pharm. Pharmacol. 61:5 (2009), 669–675.
32. Kharia, A.A., Singhai, A.K., Development and optimisation of mucoadhesive nanoparticles of acyclovir using design of experiments approach. J. Microencapsul. 32:6 (2015), 521–532.
33. Kulkarni, V., Shaw, C., Formulation and characterization of nasal sprays: an examination of nasal spray formulation parameters and excipients and their influence on key in vitro tests. Inhalation, 2012, 10–15.
34. Kumar, M., Misra, A., Babbar, A.K., Mishra, A.K., Mishra, P., Pathak, K., Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int. J. Pharm. 358:1 (2008), 285–291.
35. Kumar, A., Pandey, A.N., Jain, S.K., Nasal-nanotechnology: revolution for efficient therapeutics delivery. Drug deliv. 23:3 (2016), 681–693.
36. Lawrence, M.J., Rees, G.D., Microemulsion-based media as novel drug delivery systems. Adv. Drug Deliv. Rev. 64 (2000), 175–193.
37. Lu, C.T., Zhao, Y.Z., Wong, H.L., Cai, J., Peng, L., Tian, X.Q., Current approaches to enhance CNS delivery of drugs across the brain barriers. Int. J. Nanomedicine 9 (2014), 2241–2257.
38. Mandal, S., Mandal, S.D., Design and development of carbamazepine mucoadhesive microemulsion for intranasal delivery: an ex-vivo study. Int. J. Pharm. Sci. Rev. Res. 3 (2010), 56–60.
39. Mittal, D., Ali, A., Md, S., Baboota, S., Sahni, J.K., Ali, J., Insights into direct nose to brain delivery: current status and future perspective. Drug Deliv. 21:2 (2014), 75–86.
40. Mittal, D., Md, S., Hasan, Q., Fazil, M., Ali, A., Baboota, S., Ali, J., Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route. Drug Deliv. 23:1 (2016), 130–139.
41. Miyamoto, S., Duncan, G.E., Marx, C.E., Lieberman, J.A., Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 10 (2005), 79–104.
42. Patel, N., Baldaniya, M., Raval, M., Sheth, N., Formulation and development of in situ nasal gelling systems for quetiapine fumarate-loaded mucoadhesive microemulsion. J. Pharm. Innov. 10:4 (2015), 357–373.
43. Patel, R.B., Patel, M.R., Bhatt, K.K., Patel, B.G., Gaikwad, R.V., Evaluation of brain targeting efficiency of intranasal microemulsion containing olanzapine: pharmacodynamic and pharmacokinetic consideration. Drug Deliv. 23:1 (2016), 307–315.
44. Piao, H.M., Balakrishnan, P., Cho, H.J., Kim, H., Kim, Y.S., Chung, S.J., Shim, C.K., Kim, D.D., Preparation and evaluation of fexofenadine microemulsions for intranasal delivery. Int. J. Pharm. 395:1 (2010), 309–316.
45. Pouton, C.W., Formulation of self emulsifying drug delivery systems. Adv. Drug Deliv. Rev. 25 (1997), 47–58.
46. Pund, S., Rasve, G., Borade, G., Ex vivo permeation characteristics of venlafaxine through sheep nasal mucosa. Eur. J. Pharm. Sci. 48:1 (2013), 195–201.
47. Sadeque, A.J., Wandel, C., He, H., Shah, S., Wood, A.J., Increased drug delivery to the brain by P-glycoprotein inhibition. Clin. Pharmacol. Ther. 68:3 (2000), 231–237.
48. Schinkel, A.H., P-glycoprotein, a gatekeeper in the blood–brain barrier. Adv. Drug Deliv. Rev. 36 (1999), 179–194.
49. Schinkel, A.H., Jonker, J.W., Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. 55:1 (2003), 3–29.
50. Schizophrenia, National Institute of Mental Health, Available from: http://www.nimh.nih.gov/health/topics/schizophrenia/index.shtml.
51. Shah, B.M., Misra, M., Shishoo, C.J., Padh, H., Nose to brain microemulsion-based drug delivery system of rivastigmine: formulation and ex-vivo characterization. Drug Deliv. 22:7 (2015), 918–930.
52. Shah, B., Khunt, D., Bhatt, H., Misra, M., Padh, H., Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: effect on formulation and characterization parameters. Eur. J. Pharm. Sci. 78 (2015), 54–66.
53. Soeiro-de-Souza, M.G., Dias, V.V., Missio, G., Balanzá-Martinez, V., Valiengo, L., Carvalho, A.F., Moreno, R.A., Role of quetiapine beyond its clinical efficacy in bipolar disorder: from neuroprotection to the treatment of psychiatric disorders (review). Exp. Ther. Med. 9 (2015), 643–652.
54. Sood, S., Jain, K., Gowthamarajan, K., Optimization of curcumin nanoemulsion for intranasal delivery using design of experiment and its toxicity assessment. Colloids Surf., B 113 (2014), 330–337.
55. Suman, J., In vitro nasal spray characterization. Inhalation, 2009, 15–19.
56. Tajes, M., Ramos-Fernández, E., Weng-Jiang, X., Bosch-Morató, M., Guivernau, B., Eraso-Pichot, A., Salvador, B., Fernàndez-Busquets, X., Roquer, J., Muñoz, F.J., The blood-brain barrier: structure, function and therapeutic approaches to cross it. Mol. Membr. Biol. 31:5 (2014), 152–167.
57. Trows, S., Wuchner, K., Spycher, R., Steckel, H., Analytical challenges and regulatory requirements for nasal drug products in Europe and the US. Pharmatherapeutica 6:2 (2014), 195–219.
58. Vyas, T.K., Babbar, A.K., Sharma, R.K., Singh, S., Misra, A., Intranasal mucoadhesive microemulsions of clonazepam: preliminary studies on brain targeting. J. Pharm. Sci. 95:3 (2006), 570–580.
59. Washington, N., Steele, R.J.C., Jackson, S.J., Bush, D., Mason, J., Gill, D.A., Pitt, K., Rawlins, D.A., Determination of baseline human nasal pH and the effect of intranasally administered buffers. Int. J. Pharm. 198:2 (2000), 139–146.
60. World Health Organization (WHO). Schizophrenia. Fact sheet N 397. September 2014, Available from: http://www.who.int/mediacentre/factsheets/fs397/en/.
61. Yeh, T.H., Hsu, L.W., Tseng, M.T., Lee, P.L., Sonjae, K., Ho, Y.C., Sung, H.W., Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening. Biomaterials 32:26 (2011), 6164–6173.
62. Yuan, Y., Lee, T.R., Contact angle and wetting properties. Bracco, G., Holst, B., (eds.) Surface Science Techniques, 2013, Springer Berlin-Heidelberg, New York, 3–29.
63. Zerrouk, N., Corti, G., Ancillotti, S., Maestrelli, F., Cirri, M., Mura, P., Influence of cyclodextrins and chitosan, separately or in combination, on glyburide solubility and permeability. Eur. J. Pharm. Biopharm. 62:3 (2006), 241–246.